Morphoproteomics demonstrates activation of mammalian target of rapamycin pathway in papillary thyroid carcinomas with nuclear translocation of MTOR in aggressive histological variants

Modern Pathology

Volumn 24, Issue 12, 2011, Pages 1553-1559

  Liu, Jing ^a   Brown, Robert E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Akt; immunohistochemistry; mammalian target of rapamycin; morphoproteomics; papillary thyroid carcinoma

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN;

ARTICLE; BLOOD VESSEL; CANCER INVASION; CANCER SIZE; CLINICAL ARTICLE; ENZYME ACTIVATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MORPHOLOGY; MORPHOPROTEOMICS; PRIORITY JOURNAL; PROTEOMICS; SIGNAL TRANSDUCTION; THYROID CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

ACTIVE TRANSPORT, CELL NUCLEUS; CELL NUCLEUS; ENZYME ACTIVATION; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROGNOSIS; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 82555167108     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.121     Document Type: Article

References (38)

1. Livolsi VA, Albores-Saavedra J, Asa SL, et al. Papillary carcinoma In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds). WHO classification of tumors-pathology and genetics of tumours of endocrine organs. IARC press: Lyon, France, 2004, pp 57-66.
2. Nikiforov YE, Ohori NP. Papillary carcinoma In: Nikiforov YE, Biddinger PW, Thompson LDR (eds). Diagnostic pathology and molecular genetics of the thyroid. Wolters Kluwer/Lippincott William & Wilk-ins: Philadelphia, Pennsylvania, 2009, pp 160-213.
3. Johnson TL, Lloyd RV, Thompson NW, et al. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol 1988;12:22-27. (Pubitemid 18024370)
4. Evans HL. Columnar-cell carcinoma of the thyroid. A report of two cases of an aggressive variant of thyroid carcinoma. Am J Clin Pathol 1986;85:77-80. (Pubitemid 16166045)
5. Fukushima M, Ito Y, Hirokawa M, et al. Clinicopatho-logic characteristics and prognosis of diffuse sclerosing variant of papillary thyroid carcinoma in Japan: an 18-year experience at a single institution. World J Surg 2009;33:958-962.
6. Falvo L, Giacomelli L, D'Andrea V, et al. Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Am Surg 2006;72:438-444. (Pubitemid 46940744)
7. Hay ID, Grant CS, Taylor WF, et al. Ipsilateral versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088-1095. (Pubitemid 18010757)
8. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma. A study of the EORTC thyroid cancer cooperative group. Eur J Cancer 1979; 15:1033-1041. (Pubitemid 9254743)
9. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988;104:947-953. (Pubitemid 19011971)
10. Smith RA, Salajegheh A, Weinstein S, et al. Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol 2010;42:500-506.
11. Lloyd RV, Buehler D, Khanafshar E. Papillary thyroid carcinoma variants. Head Neck Pathol 2011;5: 51-56.
12. Tang KT, Lee CH. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc 2010;73:113-128.
13. Hou P, Bojdani E, Xing M. Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J Clin Endocrinol Metab 2010;95:820-828.
14. Jin N, Jiang T, Rosen DM, et al. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplas-tic thyroid cancer. J Clin Endocrinol Metab 2009; 94:4107-4112.
15. Rocha AS, Paternot S, Coulonval K, et al. Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation. Mol Biol Cell 2008;19:4814-4825.
16. Liu D, Hou P, Liu Z, et al. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 2009;69:7311-7319.
17. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2005;23:5294-5304. (Pubitemid 46206983)
18. Agarwala SS, Case S. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist 2010;15:236-245.
19. Antonarakis ES, Carducci MA, Eisenberger MA. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2010;291:1-13.
20. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-484. (Pubitemid 43199434)
21. Guerin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22. (Pubitemid 47001784)
22. Nojima H, Tokunaga C, Eguchi S, et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOR) motif. J Biol Chem 2003;278:15461-15464. (Pubitemid 36799651)
23. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007;12:487-502. (Pubitemid 46523652)
24. Brown RE. Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Rev Proteomics 2005; 2:337-348. (Pubitemid 40839745)
25. Lin F, Zhang PL, Yang XJ, et al. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci 2006;36:283-293. (Pubitemid 44320422)
26. Feng W, Brown RE, Trung CD, et al. Morphoproteomic profile of mTOR, ras/raf kinase/ERK, and NF-kB pathways in human gastric adenocarcinoma. Ann Clin Lab Sci 2008;38:195-209.
27. Brown RE, Zhang PL, Lun M, et al. Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma. Ann Clin Lab Sci 2006;36: 273-282. (Pubitemid 44320421)
28. Cao X, Kambe F, Moeller LC, et al. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts. Mol Endocrinol 2005;19:102-112. (Pubitemid 40065962)
29. Reinhard C, Fernandez A, Lamb NJC, et al. Nuclear localization of p85s6k: functional requirement for entry into S phase. EMBO J 1994;13:1557-1565.
30. Rosner M, Hengstschlager M. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum Mol Genet 2008;17:2934-2948.
31. Liu J, Brown RE. Morphoproteomics demonstrates activation of mTOR pathway in anaplastic thyroid carcinoma: a preliminary observation. Ann Clin Lab Sci. 2010;40:211-217.
32. Hall MN. mTOR-what does it do? Transplant Proc 2008;40(10 suppl):S5-S8.
33. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphoryla-tion and regulation of Akt/PKB by the rector-mTOR complex. Science 2005;307:1098-1101. (Pubitemid 40262113)
34. Sparks CA, Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010;29:3733-3744.
35. Stephens L, Anderson K, Stokoe D, et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 1998;279:710-714. (Pubitemid 28144551)
36. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22. (Pubitemid 47001784)
37. Shor B, Gibbons JJ, Abraham RT, et al. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 2009;8:3831-3837.
38. Borders EB, Bivona C, Medina PJ. Mammalian target of rapamycin: biological function and target for novel anticancer agents. Am J Health Syst Pharm 2010;67: 2095-2106.